| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRUROL.2010.207 |
| P698 | PubMed publication ID | 21228820 |
| P50 | author | Clement Ho | Q43262543 |
| P2093 | author name string | Fouad K Habib | |
| P2860 | cites work | 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. | Q45927518 |
| Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia | Q46340150 | ||
| The identification and simultaneous quantification of 7-hydroxylated metabolites of pregnenolone, dehydroepiandrosterone, 3beta,17beta-androstenediol, and testosterone in human serum using gas chromatography-mass spectrometry | Q46502522 | ||
| Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin | Q47784018 | ||
| Androgen receptor protein expression in prostatic tissues in Black and Caucasian men. | Q47816327 | ||
| Natural potent androgens: lessons from human genetic models | Q50847801 | ||
| The effects of chronic high dose androgen or estrogen treatment on the human prostate [corrected] | Q50986851 | ||
| Calculated free testosterone in men: comparison of four equations and with free androgen index | Q51931249 | ||
| The Natural History and Course of Untreated Benign Prostatic Hyperplasia | Q52239147 | ||
| Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias | Q53692984 | ||
| Effects of estrogen deprivation on human benign prostatic hyperplasia | Q54051530 | ||
| In vivo uptake and metabolism of 3H-testosterone and 3H-5 -dihydrotestosterone by human benign prostatic hypertrophy | Q54265833 | ||
| Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia | Q56114101 | ||
| Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate | Q57248630 | ||
| Polymorphisms in the Vitamin D Receptor Gene and the Androgen Receptor Gene and the Risk of Benign Prostatic Hyperplasia | Q57307315 | ||
| Human prostatic cells in culture: Different testosterone metabolic profile in epithelial cells and fibroblasts from normal or hyperplastic prostates | Q57565389 | ||
| Estrogen receptor β expression in human prostate tissue | Q61759637 | ||
| Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients | Q67465301 | ||
| Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues | Q67465568 | ||
| Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate | Q67532187 | ||
| Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency | Q67557590 | ||
| Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia | Q67708308 | ||
| Regulation of estrogen and progestin receptor concentrations in an experimental rat prostatic carcinoma by estrogen, antiestrogen, and progesterone | Q68949302 | ||
| Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia | Q68979568 | ||
| Cloning and Characterization of Human Estrogen Receptor β Isoforms | Q24309303 | ||
| Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism | Q24311401 | ||
| Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human | Q24317428 | ||
| Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases | Q24558620 | ||
| Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase | Q24561410 | ||
| Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression | Q24596101 | ||
| Chemistry and structural biology of androgen receptor | Q24685498 | ||
| Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials | Q24795452 | ||
| Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone | Q27646416 | ||
| Estrogen receptor interaction with co-activators and co-repressors | Q28140995 | ||
| Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern | Q28256533 | ||
| Steroid 5 alpha-reductase 2 deficiency | Q28257380 | ||
| A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men | Q28275775 | ||
| Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta | Q28283637 | ||
| Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta | Q28304508 | ||
| Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism | Q28340320 | ||
| The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay | Q28570252 | ||
| Identification and characterization of estrogen receptor variants in prostate cancer cell lines | Q30306798 | ||
| Gene expression profiles in human BPH: utilization of laser-capture microdissection and quantitative real-time PCR. | Q30827732 | ||
| Differential regulation of testosterone vs. 5alpha-dihydrotestosterone by selective androgen response elements | Q30875476 | ||
| Selective estrogen receptor modulators: structure, function, and clinical use. | Q30912456 | ||
| Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging | Q31831299 | ||
| Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review | Q31973506 | ||
| Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells | Q33637491 | ||
| Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated | Q33733756 | ||
| Estrogen in the etiopathogenesis of BPH. | Q33764040 | ||
| Aromatase and intracrinology of estrogen in hormone-dependent tumors | Q33764638 | ||
| Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry | Q33854377 | ||
| The putative androgen receptor-A form results from in vitro proteolysis | Q33956062 | ||
| Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia | Q33961645 | ||
| Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease | Q33984042 | ||
| Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis | Q34060232 | ||
| Estrogen receptors: selective ligands, partners, and distinctive pharmacology | Q34063578 | ||
| Human prostatic steroid 5α-reductase isoforms—A comparative study of selective inhibitors | Q34296942 | ||
| Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor | Q34318703 | ||
| CYP7B generates a selective estrogen receptor beta agonist in human prostate | Q34325028 | ||
| Role of 5 alpha-reductase in health and disease | Q34334453 | ||
| Serum sex hormones and measures of benign prostatic hyperplasia | Q34340291 | ||
| Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas | Q34403345 | ||
| Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene | Q34538112 | ||
| Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. | Q34779986 | ||
| Serum sex steroids, gonadotrophins and sex hormone-binding globulin in prostatic hyperplasia | Q34781434 | ||
| Estradiol in elderly men. | Q34800127 | ||
| Regulation of testicular function in men: implications for male hormonal contraceptive development | Q35207775 | ||
| Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. | Q35580104 | ||
| Estrogen receptor expression in prostate cancer and premalignant prostatic lesions | Q35787781 | ||
| Enzymes of Androgen Formation and Degradation in the Human Prostate | Q36587799 | ||
| Cell-type-specific expression of rat steroid 5 alpha-reductase isozymes | Q36588621 | ||
| Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis | Q36700830 | ||
| Cloning, expression and functional characterization of type 1 and type 2 steroid 5 alpha-reductases from Cynomolgus monkey: comparisons with human and rat isoenzymes | Q36702228 | ||
| Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal | Q36992492 | ||
| Comparison of spontaneous and experimentally induced canine prostatic hyperplasia | Q37041803 | ||
| A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia | Q37115315 | ||
| Prostate stem cells and benign prostatic hyperplasia | Q37127502 | ||
| Expression of steroidogenic enzymes and sex-steroid receptors in human prostate | Q37159869 | ||
| 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction | Q37159919 | ||
| Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp | Q37297335 | ||
| Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial | Q37305883 | ||
| Etiology and disease process of benign prostatic hyperplasia | Q38211704 | ||
| The induction of prostatic hypertrophy in the dog with androstanediol | Q39391653 | ||
| Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate | Q39404337 | ||
| Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients | Q39461920 | ||
| Origin and evolution of benign prostatic enlargement | Q39475457 | ||
| The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia | Q39484078 | ||
| Conversion of Androstenedione to Estrone in Human Fibroblasts Cultured from Prostate, Genital and Nongenital Skin | Q39587840 | ||
| The endocrinology and developmental biology of the prostate | Q39669602 | ||
| Hormonal control of sexual development | Q39750426 | ||
| Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells | Q39847278 | ||
| The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. | Q40021719 | ||
| Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2. | Q40073163 | ||
| Effect of increasing ratio of estrogen: androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP. | Q40382742 | ||
| Physiology of the steroid-thyroid hormone nuclear receptor superfamily | Q40707712 | ||
| The androgen receptor: an overview. | Q40734794 | ||
| Age, Disease, and Changing Sex Hormone Levels in Middle-Aged Men: Results of the Massachusetts Male Aging Study* | Q41140274 | ||
| Changes in the Metabolism of Dihydrotestosterone in the Hyperplastic Human Prostate* | Q41542157 | ||
| Aromatase expression in health and disease | Q41546408 | ||
| Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue | Q41648922 | ||
| The localisation and expression of 5 alpha-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures | Q42455029 | ||
| Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates | Q42466077 | ||
| Androgen receptor expression in human tissues: an immunohistochemical study | Q42471568 | ||
| Expression of estrogen receptor in diseased human prostate assessed by non-radioactive in situ hybridization and immunohistochemistry | Q42475186 | ||
| Cell type specific expression of steroid 5 alpha-reductase 2. | Q42494852 | ||
| An estrogen receptor beta isoform that lacks exon 5 has dominant negative activity on both ERalpha and ERbeta | Q42498660 | ||
| Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate | Q42513600 | ||
| Induction of apoptosis in human prostate stromal cells by 4-hydroxytamoxifen: an alternative therapy for benign prostate hyperplasia | Q42636874 | ||
| Effects of androgen deficiency and replacement on prostate zonal volumes | Q43585997 | ||
| Regional morphology and pathology of the prostate | Q43774277 | ||
| Sex Hormones and Age: A Cross-sectional Study of Testosterone and Estradiol and Their Bioavailable Fractions in Community-dwelling Men | Q43837276 | ||
| A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia | Q44153262 | ||
| The effect of androgen, estrogen, and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates | Q44564187 | ||
| Study of 202 Natural, Synthetic, and Environmental Chemicals for Binding to the Androgen Receptor | Q44622741 | ||
| Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue | Q44692172 | ||
| Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. | Q44779375 | ||
| Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia | Q45142870 | ||
| Intratissular androgens in benign prostatic hyperplasia and prostatic cancer | Q68983598 | ||
| The possibility of aromatization of androgen in human prostate | Q69000002 | ||
| Metabolism of androgens in human benign prostatic hyperplasia: aromatase and its inhibition | Q69013900 | ||
| Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma | Q69251928 | ||
| Characterization of Chinese hamster ovary cell lines expressing human steroid 5 alpha-reductase isozymes | Q70469417 | ||
| Kinetic analysis of steroid 5alpha-reductase activity at neutral pH in benign prostatic hyperplastic tissue: evidence for type I isozyme activity in the human prostate | Q71114334 | ||
| Plasma androgens in childhood and adolescence | Q71232762 | ||
| A and B forms of the androgen receptor are expressed in a variety of human tissues | Q71538811 | ||
| Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and carcinoma | Q71600030 | ||
| Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer | Q71621838 | ||
| Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: oestrogen regulation of the androgen receptor | Q71669849 | ||
| Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group | Q71697221 | ||
| Potential activities of androgen metabolizing enzymes in human prostate | Q71703443 | ||
| Benign Prostatic Hyperplasia In A Transgenic Mouse: A New Hormonally Sensitive Investigatory Model | Q72070766 | ||
| Immunocytochemical localization of human 5 alpha-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues | Q72363502 | ||
| Relationships between oestradiol-17 beta, testosterone, dihydrotestosterone and 5 alpha-androstane-3 alpha, 27 beta-diol in human benign hypertrophy and carcinoma of the prostate | Q72629594 | ||
| Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy | Q72635320 | ||
| Failure of human benign prostatic hyperplasia to aromatise testosterone | Q72674438 | ||
| Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate | Q72728677 | ||
| The development of human benign prostatic hyperplasia with age | Q72743475 | ||
| Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia | Q73106501 | ||
| A new actor in the estrogen receptor drama--enter ER-beta | Q73106837 | ||
| Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth | Q73139226 | ||
| Aromatase in hyperplasia and carcinoma of the human prostate | Q73317174 | ||
| Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate | Q73592318 | ||
| Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation | Q73923040 | ||
| Herbal medications in the treatment of benign prostatic hyperplasia (BPH) | Q74440972 | ||
| A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project | Q74619026 | ||
| Intratumoral Aromatase in Human Breast, Endometrial, and Ovarian Malignancies* | Q77481740 | ||
| Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue | Q78030401 | ||
| Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH | Q78040597 | ||
| Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III) | Q80185157 | ||
| Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property | Q80539419 | ||
| Expression of enzymes involved in estrogen metabolism in human prostate | Q83228628 | ||
| The effect of orchiectomy and estrogens of benign prostatic hyperplasia | Q93724078 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| pathogenesis | Q372016 | ||
| P304 | page(s) | 29-41 | |
| P577 | publication date | 2011-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Nature Reviews Urology | Q2079265 |
| P1476 | title | Estrogen and androgen signaling in the pathogenesis of BPH | |
| P478 | volume | 8 |
| Q38107993 | ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development |
| Q36838223 | Action Mechanism ofGinkgo bilobaLeaf Extract Intervened by Exercise Therapy in Treatment of Benign Prostate Hyperplasia |
| Q41788361 | Age-related histological and zinc content changes in adult nonhyperplastic prostate glands |
| Q35651459 | Androgens and esophageal cancer: What do we know? |
| Q35231660 | Androgens and estrogens in benign prostatic hyperplasia: Past, present and future |
| Q98891902 | Animal models of benign prostatic hyperplasia |
| Q41653977 | Antrodan, a β-glucan obtained from Antrodia cinnamomea mycelia, is beneficial to benign prostate hyperplasia |
| Q36941778 | Association of Circulating 25(OH)D and Lower Urinary Tract Symptoms: A Four-Year Prospective Study among Elderly Chinese Men. |
| Q35843929 | Benign prostatic hyperplasia complicated with T1DM can be alleviated by treadmill exercise-evidences revealed by the rat model |
| Q34584590 | Bisphenol A Exposure during Adulthood Alters Expression of Aromatase and 5α-Reductase Isozymes in Rat Prostate |
| Q35223985 | Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! |
| Q37652222 | CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway |
| Q85394166 | Chronic caffeine intake increases androgenic stimuli, epithelial cell proliferation and hyperplasia in rat ventral prostate |
| Q33735698 | Compounds from Cynomorium songaricum with Estrogenic and Androgenic Activities Suppress the Oestrogen/Androgen-Induced BPH Process |
| Q57488938 | Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats |
| Q39699530 | Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway |
| Q60920049 | Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia |
| Q37161245 | Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia |
| Q36935566 | Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men |
| Q37022102 | Elevated expression of HIF-lα in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasia |
| Q38811041 | Endocrine control of benign prostatic hyperplasia. |
| Q89036930 | Environmental estrogens have an impact on the ERs and their signaling in ER-responsive tissues and organs |
| Q33832224 | Expression and Function of the Progesterone Receptor in Human Prostate Stroma Provide Novel Insights to Cell Proliferation Control |
| Q50876156 | Fibroblast growth factor, estrogen, and prolactin receptor features in different grades of prostatic adenocarcinoma in elderly men |
| Q94474976 | Giant prostatic hyperplasia and its causes |
| Q38259547 | In silico analysis of the conservation of human toxicity and endocrine disruption targets in aquatic species |
| Q37989170 | Involvement of estrogen receptors in prostatic diseases |
| Q37720293 | Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. |
| Q38786798 | Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies? |
| Q89861938 | Metabolomic Analysis of Morus Cultivar Root Extracts and Their Ameliorative Effect on Testosterone-Induced Prostate Enlargement in Sprague-Dawley Rats |
| Q42371431 | Musulju improves benign prostatic hyperplasia by regulating inflammatory and apoptotic proteins |
| Q37018606 | NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. |
| Q36606285 | NF-κB and androgen receptor variant expression correlate with human BPH progression |
| Q92229189 | Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase |
| Q87706189 | Pharmacology of the lower urinary tract |
| Q49719390 | Potential of Moringa oleifera in the Treatment of Benign Prostate Hyperplasia: Role of Antioxidant Defence Systems. |
| Q42200788 | Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia |
| Q37074170 | Relationship between serum sex hormones levels and degree of benign prostate hyperplasia in Chinese aging men |
| Q42739837 | Reply to the commentary entitled "Environmental estrogens have an impact on the ERs and their signaling in ER responsive tissues and organs" by Xu-Guang Guo. |
| Q38115066 | Selective estrogen receptor modulators for BPH: new factors on the ground. |
| Q48824369 | Stimulatory Adrenocortical Effects of a Selective Estrogen Receptor Modulator in Ovariectomized Female Macaques |
| Q36993287 | The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis |
| Q40973775 | The Prevalence and Association of Varicoceles on Male Patients With Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms |
| Q50920454 | The Variation with Age of 67 Macro- and Microelement Contents in Nonhyperplastic Prostate Glands of Adult and Elderly Males Investigated by Nuclear Analytical and Related Methods |
| Q89005504 | The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH) |
| Q36360868 | Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate |
| Q43892537 | Vanillic acid attenuates testosterone-induced benign prostatic hyperplasia in rats and inhibits proliferation of prostatic epithelial cells |
Search more.